SubsidieMeestersA new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Projectdetails
Introduction
Ischemic Heart Disease kills more than 1.7M people/year in the EU, the vast majority via a heart attack (Myocardial Infarction - MI).
Background
Heart failure (HF) is the major cause of death after MI, with a prevalence of >26M individuals globally. While current treatment involving restoration of blood flow to the heart saves the MI patient’s life, it also causes additional damage to the heart through an inflammatory reaction (reperfusion injury).
Drug Candidate
ResoTher’s leading drug candidate, RTP-026, is an immunomodulating therapeutic aimed at resolving inflammation triggered during MI. This approach is designed to reduce damage to the heart and significantly decrease the risk of HF and death.
Pre-clinical Data
Pre-clinical data suggests RTP-026 could reduce post-MI HF by >20%.
Clinical Studies
A Phase I study has been conducted to determine the safety and tolerability of RTP-026 in Healthy Volunteers.
Future Plans
With the EIC, we aim to validate RTP-026 clinical effectiveness by means of:
- A Phase IIa patient proof of principle study
- A Phase IIb proof of concept study
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 3.770.625 |
Tijdlijn
| Startdatum | 1-2-2024 |
| Einddatum | 31-1-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- RESOTHER PHARMA A/Spenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes. | EIC Accelerator | € 2.306.500 | 2024 | Details |
Autonomous robotics and digital TWIN to improve water network performancesThe project develops a robotic inspection system for water utilities, enabling autonomous pipeline assessments to enhance water quality and sustainability through a subscription-based RaaS model. | EIC Accelerator | € 2.478.210 | 2024 | Details |
Toopi Regen: Unleash the power of urine to finally scale a real closed loop and regenerative farming systemToopi Organics aims to revolutionize agriculture by up-cycling human urine into sustainable biostimulants, reducing reliance on mineral fertilizers while enhancing soil health and farmer profitability. | EIC Accelerator | € 2.396.457 | 2024 | Details |
Miniaturised Respiratory Assist to treat acute lung failure patients using a breakthrough hyperbaric technologyHBOX Therapies aims to commercialize MiRA, a novel hyperoxygenation therapy for acute lung failure, enhancing patient outcomes while reducing reliance on invasive ventilation. | EIC Accelerator | € 2.499.999 | 2024 | Details |
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""
NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes.
Autonomous robotics and digital TWIN to improve water network performances
The project develops a robotic inspection system for water utilities, enabling autonomous pipeline assessments to enhance water quality and sustainability through a subscription-based RaaS model.
Toopi Regen: Unleash the power of urine to finally scale a real closed loop and regenerative farming system
Toopi Organics aims to revolutionize agriculture by up-cycling human urine into sustainable biostimulants, reducing reliance on mineral fertilizers while enhancing soil health and farmer profitability.
Miniaturised Respiratory Assist to treat acute lung failure patients using a breakthrough hyperbaric technology
HBOX Therapies aims to commercialize MiRA, a novel hyperoxygenation therapy for acute lung failure, enhancing patient outcomes while reducing reliance on invasive ventilation.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
Harnessing Novel Micropeptides in Cardiomyocytes to promote Cardiac RegenerationNovel.CaRe aims to enhance cardiac regeneration post-myocardial infarction by using micropeptides to stimulate cardiomyocyte proliferation and maturation through innovative gene therapy approaches. | ERC STG | € 1.592.281 | 2024 | Details |
A Multi-Omics Approach for Novel Drug Targets, Biomarkers and Risk Algorithms for Myocardial InfarctionTargetMI aims to rapidly discover novel drug targets and biomarkers for myocardial infarction using a high-throughput multi-omic approach on 1000 samples, enhancing clinical risk prediction and translation. | EIC Pathfinder | € 3.999.840 | 2023 | Details |
Optimize risk prediction after myocardial infarction through artificial intelligence and multidimensional evaluationThis project aims to enhance myocardial infarction risk prediction by integrating data from wearable devices, biomarkers, and AI to identify novel risk factors for improved clinical decision-making. | ERC STG | € 1.405.894 | 2024 | Details |
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
Harnessing Novel Micropeptides in Cardiomyocytes to promote Cardiac Regeneration
Novel.CaRe aims to enhance cardiac regeneration post-myocardial infarction by using micropeptides to stimulate cardiomyocyte proliferation and maturation through innovative gene therapy approaches.
A Multi-Omics Approach for Novel Drug Targets, Biomarkers and Risk Algorithms for Myocardial Infarction
TargetMI aims to rapidly discover novel drug targets and biomarkers for myocardial infarction using a high-throughput multi-omic approach on 1000 samples, enhancing clinical risk prediction and translation.
Optimize risk prediction after myocardial infarction through artificial intelligence and multidimensional evaluation
This project aims to enhance myocardial infarction risk prediction by integrating data from wearable devices, biomarkers, and AI to identify novel risk factors for improved clinical decision-making.